FDA Approves Pfizer COVID-19 Pill Which Reduces Death, Severe Disease

FDA Approves Pfizer COVID-19 Pill Which Reduces Death, Severe Disease
A coronavirus. CDC: Dr. Fred Murphy & Sylvia Whitfield

By Dylan Housman

The Food and Drug Administration (FDA) approved Pfizer’s antiviral COVID-19 pill Wednesday, granting access to another highly effective therapeutic against the virus.

The drug, Paxlovid, can be prescribed to those aged 12 and up with mild or worse COVID-19 cases and is designed to reduce the risk of severe disease and hospitalization. Early supply of the drug will be limited, but eventually it is expected to provide major relief to hospitals strained by COVID-19 patients.

Trending: New York State fails to teach kids to read despite spending $30K per student

Pfizer CEO Albert Bourla said Wednesday the company will begin delivery of the pills immediately. Clinical trials of the drug found it to be 89% effective at stopping high-risk patients from developing serious disease or dying, the company said. The full course of treatment involves taking three pills twice daily for five days after infection. (RELATED: Despite Evidence, Walensky Refuses To Call Omicron ‘Mild’ In Interview With Fox’s Bret Baier)

The treatment must begin within five days of first symptoms in order to be effective, the FDA said. Bourla said there will be 180,000 courses of treatment available by the end of this year and up to 80 million available next year. The Biden administration has already made plans to purchase 10 million courses of the treatment.

Comments

For your convenience, you may leave commments below using Disqus. If Disqus is not appearing for you, please disable AdBlock to leave a comment.